We discover, develop and deliver neurological therapies for patients with unmet medical needs.
Équilibre Biopharmaceuticals Corp. was established as an innovative biopharmaceutical company focused on identifying and developing high-potential drugs for patients who are treatment resistant or unresponsive to other existing medications.
Strategy:
Our approach is to leverage our biopharmaceutical industry expertise to further expand our portfolio of product opportunities. Our business strategy is designed to be flexible and nimble, which allows us to develop a broad array of new therapies with clinical and commercial potential.
Partnerships:
We’re driven by our passion to help patients. In pursuit of the betterment of patients, we encourage and promote collaboration and teamwork among our employees and those of our partners to potentially accelerate drug developments and foster best practices.
Our goal is to be at the forefront of prolific scientific research and development with multiple programs in preclinical and clinical development. Our lead candidate EQU-001 is in Phase 2 stage of clinical development for Focal Seizures. Our pre-clinical pipeline includes treatments for various neurological disorders including infantile spasms, seizure disorders associated with traumatic brain injury and multiple sclerosis.
What’s in a
Name?
Équilibre
Our name is derived from the French phrase “tenir en équilibre,” which means to be balanced.
To help patients achieve stability, we are devoted to discovering and developing medicines that restore the consistency of the biological systems optimal for survival.
